76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Fulgent Genetics Inc
Closed
SectorHealthcare
21.19 2.71
Overview
Share price change
24h
Min
20.13
Max
21.37
Income | -5.7M -12M |
|---|---|
Sales | -2.8M 73M |
EPS | 0.04 |
Profit margin | -16.197 |
Employees | 1,313 |
EBITDA | -2M -12M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +16.11% upside |
Next Earnings | 1 Aug 2025 |
|---|
Market Cap | 57M 629M |
|---|---|
Previous open | 18.48 |
Previous close | 21.19 |
News Sentiment
By Acuity
94%
6%
366 / 381 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
Fulgent Genetics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Fulgent Genetics Inc Forecast
Price Target
By TipRanks
16.11% upside
12 Months Forecast
Average 24 USD 16.11%
High 25 USD
Low 23 USD
Based on 2 Wall Street analysts offering 12 month price targets forFulgent Genetics Inc - Dist in the last 3 months.
Sentiment
By Acuity
366 / 381 Healthcare
News Sentiment
Very Strong Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Fulgent Genetics Inc
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
